Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Parallel states of pathological Wnt signaling in neonatal brain injury and colon cancer.
Strategies for myelin regeneration: lessons learned from development.
France Banned AB Science Drug Studies Because of Side Effects
The genetics of multiple sclerosis.
Uncovering Cryptic Glycan Markers in Multiple Sclerosis (MS) and Experimental Autoimmune Encephalomyelitis (EAE).
[Cognitive performance and quality of life in multiple sclerosis in Gipuzkoa].
Simvastatin: a review.
Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes.
▼Dimethyl fumarate for relapsing-remitting multiple sclerosis.
Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease.
Trial watch: Chemotherapy with immunogenic cell death inducers.
Including known covariates can reduce power to detect genetic effects in case-control studies.
Defining high, medium and low impact prognostic factors for developing multiple sclerosis.
Quality of life in the care home: a qualitative study of the perspectives of residents with multiple sclerosis.
Oral contraceptive use and clinical outcomes in patients with multiple sclerosis.
Imaging of the spine at 3 tesla.
Effect of Glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.
Secukinumab (AIN457) showed superiority over Enbrel® in clearing skin, according to pivotal Novartis Phase III psoriasis results at EADV
Pregnancy in multiple sclerosis: a questionnaire study.
Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
Acorda Announces Initiation of Phase 3 Clinical Trial for Dalfampridine in Post-Stroke Walking Deficits
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
A unifying multiple sclerosis etiology linking virus infection, sunlight, and vitamin D, through viral interleukin-10.
Serum level of interleukin-6 in Chinese patients with multiple sclerosis.
CCSVI and MS: a statement from the European Society of neurosonology and cerebral hemodynamics.

Pages